Associated Papers
No evidence for the LRRK2 p.L1795F variant in a Southern Italian cohort with Parkinson's disease.
Gagliardi M et al.
Gene, 2026
An update on the monogenic causes of Parkinson's disease: Impact on patient stratification and personalised medicine.
Asmi S et al.
Ageing Research Reviews, 2026
APOE, Aβ42, and tau differentially impact cognitive decline in Sporadic, GBA1 and LRRK2 Parkinson's disease.
Botta R et al.
Npj Parkinson's Disease, 2026
CSF LRRK2: A biomarker for slower autonomic dysfunction progression in sporadic Parkinson's disease.
Chen S et al.
Autonomic Neuroscience : Basic & Clinical, 2026
Membrane Dysfunction as a Central Mechanism in LRRK2-Associated Parkinson's Disease: Comparative Analysis of G2019S and I1371V Variants.
Singh K et al.
Cells, 2026
Association of LRRK2 p.A419V with Parkinson's Disease in East Asians and analysis of age at onset.
Lim KS et al.
Npj Parkinson's Disease, 2026
Structural and biochemical basis of ROC-dependent activation of LRRK2.
Hoang Q et al.
Research Square, 2026
Protective or Pathogenic? Kinase activity and the neurodevelopmental origins of G2019S LRRK2-Associated Parkinson's disease.
Gatto EM et al.
Parkinsonism & Related Disorders, 2026
Multi-cohort, cross-species urinary proteomics reveals signatures of LRRK2 dysfunction in Parkinson's disease.
Vu DT et al.
Molecular Systems Biology, 2026
Discordance of Dopaminergic Dysfunction and Subcortical Atrophy by α-Synuclein Status in Sporadic and Genetic Parkinson's Disease.
Duong MT et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2026
Carriers of LRRK2 pathogenic variants show a milder, anatomically distinct brain signature of Parkinson's disease.
Kopal J et al.
Communications Medicine, 2026
The Influence of Genetics in the Early Development of Axial Postural Abnormalities in Parkinson's Disease.
Vico IAD et al.
Movement Disorders Clinical Practice, 2026
ESRRA-ATG5-Mediated mitophagy enhances arginine metabolism to alleviate diabetic kidney disease.
Hu H et al.
Autophagy, 2025
Neuropathology in genetic Parkinson's disease: a focused review of pathological and clinical findings.
Barbosa PM et al.
Journal of Neural Transmission (vienna, Austria : 1996), 2025
Plasma Levels of Food-Derived Metabolites as Biomarkers of Parkinson's Disease.
Dong X et al.
International Journal of Molecular Sciences, 2025
Long-term oral glucocerebrosidase activator reduces soluble α-synuclein oligomer accumulation in Parkinsonian LRRK2 mutant mouse brain.
Choi ZY et al.
Npj Parkinson's Disease, 2025
LRRK2 as a Potential Disease-Modifying Target in Sporadic Parkinson's Disease.
Lang AE et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2025
LRRK2 G2019S mutation contributes to mitochondrial transfer dysfunction in a Drp1-STX17-dependent manner.
Ding M et al.
Translational Neurodegeneration, 2025
The Human LRRK2-R1441G Mutation Drives Age-Dependent Oxidative Stress and Mitochondrial Dysfunction in Dopaminergic Neurons.
Chen Y et al.
Research Square, 2025
Protective role of Bre1 in mitochondrial function and energy metabolism in Drosophila models of Parkinson's disease.
Wei Z et al.
Free Radical Biology & Medicine, 2025
Animal Models of Parkinson's Disease.
Dawson VL et al.
Cold Spring Harbor Perspectives in Medicine, 2025
Motor response in monogenic LRRK2 parkinson's disease after deep brain stimulation: A systematic review and meta-analysis.
Ar Rochmah M et al.
The Medical Journal of Malaysia, 2025
Soluble immune factor profiles in blood and CSF associated with LRRK2 mutations and Parkinson's disease.
Jaffery R et al.
Npj Parkinson's Disease, 2025
Interferon gamma stimulates coordinated changes in LRRK2, GCase, and cathepsin activities in idiopathic and genetic Parkinson's disease monocytes.
Hughes LP et al.
Npj Parkinson's Disease, 2025
A Complex FGF14 (TTC)/(TGC) Repeat Expansion in Parkinson's Disease.
Zheng X et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2025
LRRK2 p.G2385R and p.R1628P variants in a multi-ethnic Asian Parkinson's Cohort: epidemiology and clinical insights.
Goh JW et al.
Npj Parkinson's Disease, 2025
Dysfunctional Alternative Polyadenylation Modifies the Penetrance of LRRK2 Variants in Parkinson's Disease.
Yang S et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2025
Mitochondrial Calcium Channels and MAM Interaction in Calcium Homeostasis Dysregulation in Parkinson's Disease.
Han B et al.
Neurochemical Research, 2025
The G2019S LRRK2 mutation exacerbates α-synuclein and tau neuropathology through divergent pathways in Parkinson's disease models.
Tsafaras G et al.
Acta Neuropathologica, 2025
Association of Sporadic and Genetic Parkinson's Disease with Cancer: Insights from the PPMI Cohort.
Sfikas E et al.
Genes, 2025
VPS35 mutation inhibits PINK1/parkin-mediated mitophagy via increased LRRK2 kinase activity.
Manders L et al.
Brain : a Journal of Neurology, 2025
LRRK2 and the fragile synapse: a molecular prelude to Parkinson's disease?
Masotti B et al.
The Biochemical Journal, 2025
Neural networks reveal novel gene signatures in Parkinson disease from single-nuclei transcriptomes.
Fiorini MR et al.
Npj Parkinson's Disease, 2025
Decreased SNCA expression in whole-blood RNA analysis of Parkinson's disease adjusting for neutrophils.
Xu KY et al.
Npj Parkinson's Disease, 2025
Large-scale genetic characterization of Parkinson's disease in the African and African admixed populations.
Akçimen F et al.
Brain : a Journal of Neurology, 2025
Functional and Structural Characterization of LRRK2 p.V1447L in Parkinson's Disease.
Pratuseviciute N et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2025
Bilateral subthalamic deep brain stimulation in Parkinson's disease with RAB32 mutation.
Samanci B et al.
Parkinsonism & Related Disorders, 2025
Parkinson's disease LRRK2 mutations dysregulate iron homeostasis and promote oxidative stress and ferroptosis in human neurons and astrocytes.
Mamais A et al.
Biorxiv : the Preprint Server for Biology, 2025
Absence of Rab39b-induced macroautophagy impairment increases neurotoxic α-synuclein and causes degeneration of substantia nigra dopaminergic neurons in mouse model of X-linked Parkinson's disease.
Chiu CC et al.
Life Sciences, 2025
The LRRK2 p.A419V variant associates with risk of Parkinson's disease in the East Asian population and an evaluation on age of onset.
Lim KS et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Clinical feature and alpha-synuclein level of restless legs syndrome with leucine-rich repeat kinase 2 encoding gene mutation.
Guo X et al.
Parkinsonism & Related Disorders, 2025
Genetic Basis of Sleep Dysfunction in Parkinson's Disease and Parkinsonism.
Wan YM et al.
Sleep Medicine Clinics, 2025
PPM1M, an LRRK2-counteracting, phosphoRab12-preferring phosphatase with a potential link to Parkinson's disease.
Chiang CY et al.
Cell Reports, 2025
Computational association in parkinson's disease SNPs with brain structural and functional alterations.
Subramaniyan S et al.
Neurogenetics, 2025
LRRK2 kinase activity regulates Parkinson's disease-relevant lipids at the lysosome.
Maloney MT et al.
Molecular Neurodegeneration, 2025
14-3-3 binding maintains the Parkinson's associated kinase LRRK2 in an inactive state.
Martinez Fiesco JA et al.
Nature Communications, 2025